CO6160237A2 - Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden - Google Patents

Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden

Info

Publication number
CO6160237A2
CO6160237A2 CO09016704A CO09016704A CO6160237A2 CO 6160237 A2 CO6160237 A2 CO 6160237A2 CO 09016704 A CO09016704 A CO 09016704A CO 09016704 A CO09016704 A CO 09016704A CO 6160237 A2 CO6160237 A2 CO 6160237A2
Authority
CO
Colombia
Prior art keywords
optionally substituted
pyrazin
imidazo
fused
formula
Prior art date
Application number
CO09016704A
Other languages
English (en)
Inventor
Alex Muci
Jeffrey T Finer
Pu-Ping Lu
Alan James Russell
Bradley P Morgan
David J Morgans Jr
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of CO6160237A2 publication Critical patent/CO6160237A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

1.- Al menos una entidad química seleccionada de compuestos de la fórmula I y compuestos de la fórmula II:y sales farmacéuticamente aceptables del mismo, en donde R1 y R4 están seleccionados, de modo independiente, de hidrógeno, halo, hidroxi, acilo opcionalmente sustituido, alquilo opcionalmente sustituido, amino opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, alcoxi opcionalmente sustituido, aminocarbonilo opcionalmente sustituido, sulfonilo, sulfanilo, sulfinilo, carboxi, alcoxicarbonilo opcionalmente sustituido y ciano; y, de modo alternativo, R4 y R1, tomados junto con cualquier átomo interviniente, forman un sistema de anillos fusionados seleccionados de arilo fusionado opcionalmente sustituido, heteroarilo fusionado opcionalmente sustituido, cicloalquilo fusionado opcionalmente sustituido y heterocicloalquilo fusionado opcionalmente sustituido; y R2 está seleccionado de alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido y heterocicloalquilo opcionalmente sustituido; siempre que R1 no sea hex-1-enilo; y también siempre que el compuesto de la fórmula I o el compuesto de la fórmula II no sea (S)-6-bromo-1-(1-feniletil)-1H-imidazo [4,5-b]pirazin-2 (3H) -ona; 1, 5, 6-trimetil-1H-imidazo [4, 5-b] pirazin-2 (3H) -ona; 1-metil-1H-imidazo [4,5-b] pirazin-2 (3H) -ona; 6-bromo-1- (3-nitrobencil)-1H-imidazo [4,5-b] pirazin-2 (3H)- ona; 5-(hidroximetil)-1,6-dimetil-1H-imidazo [4,5-b] pirazin-2(3H)- ona; o 1- (piperidin-4-il) -1H-imidazo [4,5-b] pirazin-2 (3H)-ona. 2.- Al menos una entidad química de acuerdo con la reivindicación 1, en donde R2 está seleccionado de alquilo inferior opcionalmente sustituido, cicloalquilo opcionalmente sustituido, alcoxi opcionalmente sustituido y heterocicloalquilo opcionalmente sustituido.
CO09016704A 2006-08-02 2009-02-19 Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden CO6160237A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83527206P 2006-08-02 2006-08-02
US92105407P 2007-03-30 2007-03-30

Publications (1)

Publication Number Publication Date
CO6160237A2 true CO6160237A2 (es) 2010-05-20

Family

ID=38997712

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09016704A CO6160237A2 (es) 2006-08-02 2009-02-19 Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden

Country Status (27)

Country Link
US (3) US7598248B2 (es)
EP (4) EP2995619B1 (es)
JP (4) JP5249217B2 (es)
KR (1) KR101410453B1 (es)
CN (1) CN102993204A (es)
AR (1) AR062196A1 (es)
AU (1) AU2007281468B2 (es)
BR (1) BRPI0714725B1 (es)
CA (1) CA2659336C (es)
CL (1) CL2007002252A1 (es)
CO (1) CO6160237A2 (es)
DK (2) DK2583970T3 (es)
EA (1) EA017925B1 (es)
ES (2) ES2439590T3 (es)
HK (3) HK1131785A1 (es)
HR (1) HRP20160036T1 (es)
HU (1) HUE026571T2 (es)
IL (1) IL196767A (es)
MX (1) MX2009001170A (es)
NZ (1) NZ574888A (es)
PE (1) PE20080524A1 (es)
PL (2) PL2069352T3 (es)
PT (2) PT2583970E (es)
RS (1) RS54542B1 (es)
TW (1) TWI386412B (es)
WO (1) WO2008016669A2 (es)
ZA (1) ZA200900976B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AU2007281468B2 (en) * 2006-08-02 2012-12-06 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
KR101504669B1 (ko) * 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
US7851484B2 (en) * 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
JP2011510985A (ja) * 2008-02-04 2011-04-07 サイトキネティックス， インコーポレイテッド 特定の化学的実体、組成物および方法
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
EP3091021B1 (en) 2009-10-26 2019-08-28 Signal Pharmaceuticals, LLC Methods of synthesis and purification of heteroaryl compounds
NZ603644A (en) 2010-05-24 2014-10-31 Univ Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
CA2849213A1 (en) * 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination of riluzole and ck-2017357 for treating als
TWI708605B (zh) 2011-10-19 2020-11-01 標誌製藥公司 以ｔｏｒ激酶抑制劑治療癌症
IN2014CN04037A (es) 2011-12-02 2015-10-23 Signal Pharm Llc
ES2742398T3 (es) 2012-02-24 2020-02-14 Signal Pharm Llc Métodos para tratar el cáncer de pulmón no microcítico usando una terapia de combinación de inhibidores de TOR quinasa
EP2834269A4 (en) * 2012-04-02 2015-12-30 Cytokinetics Inc METHODS FOR IMPROVING DIAPHRAGM FUNCTION
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
CA2897985A1 (en) 2013-01-16 2014-07-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EP2986322A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
NZ730189A (en) 2013-04-17 2018-09-28 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
JP2016516818A (ja) 2013-04-17 2016-06-09 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及びｎ−（３−（５−フルオロ−２−（４−（２−メトキシエトキシ）フェニルアミノ）ピリミジン−４−イルアミノ）フェニル）アクリルアミドを含む組合せ療法
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
SG10201708111YA (en) 2013-04-17 2017-11-29 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP2986321A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
CN113831345A (zh) 2013-05-29 2021-12-24 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
HUE057533T2 (hu) 2014-04-29 2022-05-28 Cytokinetics Inc Eljárások vitálkapacitás csökkenésének gátlására
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EP3169686A4 (en) 2014-07-14 2018-01-24 Signal Pharmaceuticals, LLC Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
RU2743424C2 (ru) * 2016-02-12 2021-02-18 Астеллас Фарма Инк. Производные тетрагидроизохинолина
KR20200019229A (ko) 2017-06-22 2020-02-21 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
AR124008A1 (es) * 2020-11-06 2023-02-01 Cytokinetics Inc 1,4-diazepanonas bicíclicas y sus usos terapéuticos

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US3507866A (en) * 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
IT1156732B (it) * 1978-05-10 1987-02-04 Roussel Maestretti Spa Derivati sostituiti dell'1,3-diidroimidazo(4,5-b)piridin-2-one e relativo procedimento di produzione
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
WO1989007110A1 (en) 1988-01-28 1989-08-10 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
DE68919213T2 (de) 1988-01-28 1995-05-11 Polygen Holding Corp Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5354759A (en) * 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
JPH0641135A (ja) * 1992-07-21 1994-02-15 Nippon Soda Co Ltd イミダゾプテリジン誘導体及びその製造方法
JPH0641134A (ja) 1992-07-21 1994-02-15 Nippon Soda Co Ltd ピリミドプテリジン誘導体及びその製造方法
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
EP0873361B1 (en) 1995-12-13 2006-11-02 The Regents Of The University Of California Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
KR20010052570A (ko) 1998-06-04 2001-06-25 스티븐 에프. 웨인스톡 세포 유착을 억제하는 소염성 화합물
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
SK286788B6 (sk) 1999-10-08 2009-05-07 Grnenthal Gmbh Bicyklické deriváty imidazo-3-yl-amínu, spôsob ich výroby, ich použitie a liečivá obsahujúce tieto látky
RU2002110112A (ru) 1999-10-08 2003-12-20 Грюненталь ГмбХ (DE) Бициклические производные имидазо-5-иламина
US7148380B2 (en) 2000-02-07 2006-12-12 Yisheng Zhang Bio-energy muscle relaxants
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
GB0212048D0 (en) * 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
US20040166137A1 (en) 2002-11-08 2004-08-26 Lackey John William Hetero-substituted benzimidazole compounds and antiviral uses thereof
AU2004206860B2 (en) * 2003-01-14 2010-03-18 Cytokinetics, Inc. Compounds, compositions and methods
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2005013894A2 (en) * 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
JP2007521296A (ja) 2003-07-01 2007-08-02 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧の治療のための眼科用組成物
US20050250794A1 (en) 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
EP1715855A4 (en) 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc ANTIVIRAL DRUGS
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
WO2005108374A1 (en) 2004-04-29 2005-11-17 Fmc Corporation Insecticidal diazole and triazole derivatives
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006036883A2 (en) * 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Imidazo{4,5-b}pyrazinone inhibitors of protein kinases
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
MX2007010068A (es) * 2005-02-16 2007-10-10 Schering Corp Piperazino-piperidinas con actividad antagonista de cxcr3.
US7718657B2 (en) * 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
US8796293B2 (en) * 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
TWI339283B (en) * 2006-07-14 2011-03-21 Chimei Innolux Corp Frame assembly of flat display panel
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
WO2008016648A2 (en) 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
AU2007281468B2 (en) * 2006-08-02 2012-12-06 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
KR101504669B1 (ko) * 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008075007A1 (en) 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
CN101663279A (zh) 2007-01-19 2010-03-03 阿迪生物科学公司 Mek抑制剂
US7851484B2 (en) 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
MX2009010296A (es) * 2007-04-18 2009-12-14 Kissei Pharmaceutical Derivado de anillo fusionado nitrogenado, composicion farmaceutica que lo contiene, y uso del mismo para propositos medicos.
US7998976B2 (en) * 2008-02-04 2011-08-16 Cytokinetics, Inc. Certain chemical entities, compositions and methods
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use

Also Published As

Publication number Publication date
CA2659336A1 (en) 2008-02-07
IL196767A0 (en) 2009-11-18
WO2008016669A2 (en) 2008-02-07
ES2439590T3 (es) 2014-01-23
AU2007281468A1 (en) 2008-02-07
RS54542B1 (en) 2016-06-30
JP6254546B2 (ja) 2017-12-27
JP5746254B2 (ja) 2015-07-08
AU2007281468B2 (en) 2012-12-06
PL2583970T3 (pl) 2016-05-31
PT2583970E (pt) 2016-02-08
WO2008016669A3 (en) 2008-12-11
EP2069352B9 (en) 2017-03-15
JP2009545596A (ja) 2009-12-24
US20100093741A1 (en) 2010-04-15
US20080146561A1 (en) 2008-06-19
US7956056B2 (en) 2011-06-07
EP2583970A1 (en) 2013-04-24
AR062196A1 (es) 2008-10-22
JP6538809B2 (ja) 2019-07-03
ES2558517T3 (es) 2016-02-04
EP2995619B1 (en) 2019-09-25
US7598248B2 (en) 2009-10-06
ZA200900976B (en) 2009-12-30
JP2015199737A (ja) 2015-11-12
KR20090045303A (ko) 2009-05-07
KR101410453B1 (ko) 2014-06-27
US20100210645A1 (en) 2010-08-19
BRPI0714725A2 (pt) 2013-10-15
HK1184446A1 (zh) 2014-01-24
EP2069352B1 (en) 2013-10-09
EA200900242A1 (ru) 2009-08-28
JP2018058878A (ja) 2018-04-12
EP2069352A2 (en) 2009-06-17
HK1131785A1 (en) 2010-02-05
CN102993204A (zh) 2013-03-27
CL2007002252A1 (es) 2008-02-22
PL2069352T3 (pl) 2014-03-31
JP2013173762A (ja) 2013-09-05
US8293761B2 (en) 2012-10-23
PE20080524A1 (es) 2008-06-08
PT2069352E (pt) 2014-01-02
DK2069352T5 (en) 2017-04-03
HRP20160036T1 (hr) 2016-03-25
BRPI0714725B1 (pt) 2021-05-25
TW200825087A (en) 2008-06-16
TWI386412B (zh) 2013-02-21
DK2583970T3 (en) 2015-11-16
EP2069352A4 (en) 2010-10-27
DK2069352T3 (da) 2013-12-02
EP2995619A1 (en) 2016-03-16
NZ574888A (en) 2011-07-29
EP2583970B1 (en) 2015-10-14
EA017925B1 (ru) 2013-04-30
HUE026571T2 (hu) 2016-06-28
JP5249217B2 (ja) 2013-07-31
IL196767A (en) 2013-09-30
CA2659336C (en) 2015-03-24
HK1222843A1 (zh) 2017-07-14
EP2666777A1 (en) 2013-11-27
MX2009001170A (es) 2009-05-21

Similar Documents

Publication Publication Date Title
CO6160237A2 (es) Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden
AR054365A1 (es) Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP
AR044519A1 (es) Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
BRPI0413233A (pt) novos compostos
PE20130155A1 (es) Derivados de ariletinilo
AR092955A1 (es) Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
AR056888A1 (es) Derivados de heterociclil imidazol
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
ECSP099324A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
AR047678A1 (es) Derivados de benzamidas y su uso como activadores de glucoquinasa
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR061181A1 (es) Compuestos de aziridinil-epotilona
AR063529A1 (es) Compuestos de pirazolina
AR070463A1 (es) Compuestos de amina y eter que modulan el receptor cb2
CO6321266A2 (es) Inhibidores limk2 compuestos de los cuales estan hechos y metodologia de uso
WO2009010789A3 (en) Pyrimidine derivatives 934
CO6220935A2 (es) Derivados de 1,2,4-triazol como moduladores de mglur5
AR067996A1 (es) Derivados heterociclicos de ciclopropano,composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de afecciones asociadas a receptores de histamina h3, tales como enfermedad de alzheimer y esquizofrenia,entre otros.